Literature DB >> 29313702

A comparison of scaffold-free and scaffold-based reconstructed human skin models as alternatives to animal use.

Beste Kinikoglu1.   

Abstract

Tissue engineered full-thickness human skin substitutes have various applications in the clinic and in the laboratory, such as in the treatment of burns or deep skin defects, and as reconstructed human skin models in the safety testing of drugs and cosmetics and in the fundamental study of skin biology and pathology. So far, different approaches have been proposed for the generation of reconstructed skin, each with its own advantages and disadvantages. Here, the classic tissue engineering approach, based on cell-seeded polymeric scaffolds, is compared with the less-studied cell self-assembly approach, where the cells are coaxed to synthesise their own extracellular matrix (ECM). The resulting full-thickness human skin substitutes were analysed by means of histological and immunohistochemical analyses. It was found that both the scaffold-free and the scaffold-based skin equivalents successfully mimicked the functionality and morphology of native skin, with complete epidermal differentiation (as determined by the expression of filaggrin), the presence of a continuous basement membrane expressing collagen VII, and new ECM deposition by dermal fibroblasts. On the other hand, the scaffold-free model had a thicker epidermis and a significantly higher number of Ki67-positive proliferative cells, indicating a higher capacity for self-renewal, as compared to the scaffold-based model. 2017 FRAME.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29313702     DOI: 10.1177/026119291704500607

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  1 in total

1.  3-D vascularized breast cancer model to study the role of osteoblast in formation of a pre-metastatic niche.

Authors:  Rahul Rimal; Prachi Desai; Andrea Bonnin Marquez; Karina Sieg; Yvonne Marquardt; Smriti Singh
Journal:  Sci Rep       Date:  2021-11-09       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.